Stoke Therapeutics Inc - STOK Income before deduction of interest, taxes and amortization
Stoke Therapeutics bases its future revenue on RNA technologies to combat Dravet syndrome. The development of treatments for epilepsy and vision pathologies reduces scientific risks, while success in brain therapy makes the company independent of macroeconomic factors. By comparing the absolute EBITDA dynamics on GURU.Markets, we see that 0.00 reflects the latest level of the metric, revealing the real cash resilience of the business.
Summary analytical data breakdowns for Stoke Therapeutics, Inc. (STOK)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- company total debt and liquidity indicators:
Debt to Capital Stoke Therapeutics|STOK - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Stoke Therapeutics Inc|STOK - Company Aggregate Debts|Debts to Book Capitalization Stoke Therapeutics|STOK - Company Long-Term Debt|Current Liabilities Stoke Therapeutics|Immediate Liquidity stoketherapeutics.com
- financial results and valuation multiples details:
STOK - Net Income|Projected Future Earnings Stoke Therapeutics|STOK - Price to Earnings Ratio|Market Cap to Future Earnings Ratio stoketherapeutics.com|STOK - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Stoke Therapeutics|STOK - Operating profit EBITDA|Net earnings per share for the last 12 months Stoke Therapeutics|STOK - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months stoketherapeutics.com|STOK - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Stoke Therapeutics
Summary company analytics:STOK (Stoke Corp)
This metric reflects the daily volume of operating cash flow before taxes and interest. It measures the business's actual ability to generate cash from its core operations. By analyzing operating profit in cash terms, an investor assesses the current financial stability of the asset. For Stoke Therapeutics (STOK), this metric demonstrates the efficiency of monetizing patents in the field of gene therapy. Steady growth of this indicator confirms the commercial potential of unique drugs.
Competitors of Stoke Therapeutics (STOK)
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|RGEN (Repligen) - Operating profit before deduction of amortization|RNA: Company profit before taxes, interest and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|BEAM - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|NTLA - Operating profit EBITDA|BioLife Solutions, Inc. (BLFS) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization WVE (wavelifesciences.com)|MAZE (Maze Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Sionna Therapeutics, Inc. SION|Operating profit before deduction of amortization PRME (Prime Medicine Corp)|Operating profit EBITDA Taysha Corp (TSHA)|uniQure N.V. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MGTX (meiragtx.com)|REGENXBIO - Operating profit EBITDA|Operating income before deduction of amortization Solid Biosciences Inc SLDB|OCGN: Operating profit EBITDA|Operating profit before deduction of amortization PacBio Corp|Profit before payment of interest, taxes and amortization Benitec Biopharma Inc.|designtx.com (DSGN) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Rocket Pharmaceuticals, Inc. (RCKT)|Operating income before deduction of amortization 4DMT|Lexeo Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization KRRO (Korro Bio Inc.)|EDIT - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization silence-therapeutics.com|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Codexis (CDXS) - Operating profit EBITDA|SGMO (Sangamo) - Operating profit EBITDA|Operating profit before amortization NAUT (Nautilus Biotechnology Inc)|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Operating profit before amortization|Operating profit EBITDA GBIO (Generation Bio)|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Imunon, Inc. IMNN|PHIO (phiopharma.com) - Operating profit before deduction of amortization|MBIO: Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Profit before interest, taxes and amortization Bionano BNGO|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Operating profit EBITDA bluebird bio, Inc (BLUE)|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|omegatherapeutics.com (OMGA) - Profit before interest, taxes and amortization|OMIC: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS (Syros) - Operating profit before deduction of amortization|TBIO: Company profit before taxes, interest and amortization|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|UBX: Income before deduction of interest, taxes and amortization
